EWTX - Company ID 0001710072
Edgewise Therapeutics, Inc. trades as EWTX and has a market capitalization of $5.08 B, making it the #1414 largest US-listed company by market value. This page tracks Edgewise Therapeutics, Inc. through 379 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Employee stock plan | S-8 | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Insider sale notice | 144 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| SCHEDULE 13D/A | - | 2026-04-27 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up –
Each inducement stock option has an exercise price of $30.96 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.
Each inducement stock option has an exercise price of $32.46 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.
–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –
The largest companies sharing Edgewise Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of $5.08 B as of 2026-07-09, ranking #1414 among US-listed companies.
In its latest fiscal year Edgewise Therapeutics, Inc. reported a net loss of $167.79K.